GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT02162719
- Locations
- 🇺🇸
West Virginia University Hospitals Inc, Morgantown, West Virginia, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
- Conditions
- Pancreatic NeoplasmsOvarian Neoplasms
- Interventions
- Drug: DMUC4064A
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02146313
- Locations
- 🇺🇸
Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota, Florida, United States
🇺🇸Hackensack Univ Med Ctr, Hackensack, New Jersey, United States
🇺🇸Massachusetts General Hospital., Boston, Massachusetts, United States
Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
- Conditions
- Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02141087
A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02136524
A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02092792
- Locations
- 🇺🇸
Dana Farber Cancer Inst., Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02092831
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- Conditions
- Bladder CancerNeoplasmsSolid TumorsBiliary CancerSalivary Cancer
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 673
- Registration Number
- NCT02091141
- Locations
- 🇺🇸
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
- Conditions
- Stroke
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 313
- Registration Number
- NCT02072226
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02063581
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02048709
- Locations
- 🇺🇸
Georgia Regents University, Augusta, Georgia, United States